Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$27 Mln
P/E Ratio
--
P/B Ratio
1.8
Industry P/E
--
Debt to Equity
0.06
ROE
-1.64 %
ROCE
-158.16 %
Div. Yield
0 %
Book Value
0.29
EPS
-1.42
CFO
$-337.95 Mln
EBITDA
$-413.24 Mln
Net Profit
$-421.77 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bioatla Inc (BCAB)
| -25.47 | 19.08 | -11.81 | -81.25 | -50.71 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Bioatla Inc (BCAB)
| -75.69 | -70.18 | -57.97 | -42.28 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 58.42 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011),... a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, renal cell carcinomas, colorectal cancer, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361 and BA3142, both in preclinical studies for treating multiple tumor types and solid tumors respectively. The company was founded in 2007 and is headquartered in San Diego, California. Read more
Co-Founder, CEO & Chairman
Dr. Jay M. Short Ph.D.
Co-Founder, CEO & Chairman
Dr. Jay M. Short Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Bioatla Inc (BCAB) stood at $ 52 Mln as on 31-Dec-24
The share price of Bioatla Inc (BCAB) is $0.44 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Bioatla Inc (BCAB) has given a return of -50.71% in the last 3 years.
Bioatla Inc (BCAB) has a market capitalisation of $ 27 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Bioatla Inc (BCAB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bioatla Inc (BCAB) and enter the required number of quantities and click on buy to purchase the shares of Bioatla Inc (BCAB).
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, renal cell carcinomas, colorectal cancer, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361 and BA3142, both in preclinical studies for treating multiple tumor types and solid tumors respectively. The company was founded in 2007 and is headquartered in San Diego, California.
The CEO & director of Dr. Jay M. Short Ph.D.. is Bioatla Inc (BCAB), and CFO & Sr. VP is Dr. Jay M. Short Ph.D..
There is no promoter pledging in Bioatla Inc (BCAB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Bioatla Inc (BCAB) | Ratios |
|---|---|
|
Return on equity(%)
|
-164.3
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-634.33
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Bioatla Inc (BCAB) was $0 Mln.
$-0.02
(
